Epimerox: Difference between revisions
Content deleted Content added
more |
<ref>{{cite doi|10.1371/journal.pone.0060754}}</ref> |
||
| Line 1: | Line 1: | ||
{{expert-subject|Pharmacology}} |
{{expert-subject|Pharmacology}} |
||
'''Epimerox''' is an experimental [[broad-spectrum antibiotic]] being developed by [[Rockefeller University]] and [[Astex Pharmaceuticals]]. Alsthough it was originally developed specifically to target ''[[Bacillus anthracis]]'', they claim that it is also effective against |
'''Epimerox''' is an experimental [[broad-spectrum antibiotic]] being developed by [[Rockefeller University]] and [[Astex Pharmaceuticals]]. Alsthough it was originally developed specifically to target ''[[Bacillus anthracis]]'', they claim that it is also effective against [[MRSA]],<ref>{{cite doi|10.1371/journal.pone.0060754}}</ref> and many other bacteria.<ref>{{cite web|url=http://www.biosciencetechnology.com/news/2013/04/mrsa-killing-antibiotic-developed|title=MRSA-killing Antibiotic Developed|publisher=Bioscience Technology|date=April 12 2013}}</ref> It is an inhibitor compound that blocks the creation of [[2-epimerase]], an [[epimerase]] [[enzyme]].<ref>{{cite web|url=http://www.nyas.org/publications/ebriefings/Detail.aspx?cid=3642d5e1-7354-4d1d-a706-8db429235930|title= |
||
A New Era: The Fight Against Antibiotic-Resistant Pathogenic Bacteria|publisher=New York Academy of Sciences|date=December 21, 2011}}</ref><ref>{{cite web|url=http://www.decodedscience.com/new-universal-antibiotic/28322|title=New Anthrax-Killing Antibiotic Also Eliminates MRSA|author=Michael Manning|date=April 14, 2013}}</ref> |
A New Era: The Fight Against Antibiotic-Resistant Pathogenic Bacteria|publisher=New York Academy of Sciences|date=December 21, 2011}}</ref><ref>{{cite web|url=http://www.decodedscience.com/new-universal-antibiotic/28322|title=New Anthrax-Killing Antibiotic Also Eliminates MRSA|author=Michael Manning|date=April 14, 2013}}</ref> |
||
Revision as of 11:25, 16 April 2013
 | This article needs attention from an expert in Pharmacology. Please add a reason or a talk parameter to this template to explain the issue with the article. |
Epimerox is an experimental broad-spectrum antibiotic being developed by Rockefeller University and Astex Pharmaceuticals. Alsthough it was originally developed specifically to target Bacillus anthracis, they claim that it is also effective against MRSA,[1] and many other bacteria.[2] It is an inhibitor compound that blocks the creation of 2-epimerase, an epimerase enzyme.[3][4]
References
- ^ Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1371/journal.pone.0060754, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with
|doi=10.1371/journal.pone.0060754instead. - ^ "MRSA-killing Antibiotic Developed". Bioscience Technology. April 12 2013.
{{cite web}}: Check date values in:|date=(help) - ^ "A New Era: The Fight Against Antibiotic-Resistant Pathogenic Bacteria". New York Academy of Sciences. December 21, 2011.
- ^ Michael Manning (April 14, 2013). "New Anthrax-Killing Antibiotic Also Eliminates MRSA".
 | This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |